Table 3.
Research showing the effect of different drugs on FKBP5.
Type of study | Treatment | Participants | Observations | References |
---|---|---|---|---|
In vitro | Citalopram hydrobromide with dexamethasone | Human neuroblastoma cell line | Increased in the FKBP5 mRNA expression | Verjee et al. (169) |
Cohort | Citalopram | 387 patients with major depressive episodes | Interaction effects between FKBP5 with remission of depressive episodes were found | Horstmann et al. (135) |
Randomized controlled trial | Citalopram | 1,523 patients with non-psychotic depression | Association between citalopram and FKBP5 expression found | Lekman et al. (133) |
Clinical trial | Paroxetine | 131 patients suffered from moderate to severe depression | An increase in suicidal ideation within rs1360780 of FKBP5 | Perroud et al. (170) |
Venlafaxine | ||||
Cross-sectional | Clozapine | 591 cases of schizophrenia | Association between poor response to clozapine and the FKBP5-rs1360780 polymorphism | Mitjans et al. (171) |
In silico | Enzalutamide | Prostate cancer cell line | The downregulation of FKBP5 can cause enzalutamide resistance | Zheng et al. (172) |
In vivo | Icariin | 50 rats | Icariin can cause the downregulation of the FKBP5 in the hippocampus but not in the prefrontal cortex | Wei et al. (173) |
Trial | Prednisolone/liposomal encapsulated prednisolone | Male recipients are injected daily with 5 mg/kg cyclosporine and either 10 mg/kg prednisolone | The FKBP5 upregulation in liposomal-encapsulated prednisolone receptors than prednisolone or no additional treatment group | van Alem et al. (174) |
In vivo | Dexamethasone | 108 mice under stress | Alteration in FKBP5-mediated glucocorticoid sensitivity | Sawamura et al. (175) |
Case-control | Dexamethasone | 89 MDD cases vs. 126 control group | Correlation between FKBP5 rs9470079-A and a reduced cortisol suppression response to very low dose of dexamethasone | Ferrer et al. (152) |
In vivo | Dexamethasone | 100 rats under unpredictable and stressful situations | Increase FKBP5 level | Xu et al. (176) |
In vitro | Dexamethasone | Human ovary cells | Significant mRNA increase compared with the control, confirming that the GC receptor was functional and available in human fetal ovaries | Poulain et al. (177) |
In vitro | Dexamethasone | 50 patients' peripheral blood mononuclear cells (PBMC) | FKPB5 expression was induced by dexamethasone | Baptista et al. (178) |
In vitro | Dexamethasone | Human trabecular meshwork cells | Demethylated the cytosine-phosphate-guanine (CpG) sites within FKBP5 gene promotor region | Matsudaet al. (179) |
Case-control | Chlorpromazine | 40 cases with first-episode psychosis, 45 cases with schizophrenia (n = 85) vs. 56 controls | A decrease in methylation of FKBP5, or indeed a higher expression of FKBP5 | Misiak et al. (180) |
Cohort | Chlorpromazine | 55 cases of schizophrenia and 34 cases of bipolar disorder | An increase in FKBP5 expression | Sinclair et al. (181) |